A therapeutic dose of zolpidem has limited abuse-like effects in drug-naïve females: A pilot study

European Journal of Pharmacology

Volumn 598, Issue 1-3, 2008, Pages 64-67

  Licata, Stephanie C ^a   Penetar, David M ^a   Dunlap, Steven ^a   Lukas, Scott E ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

Abuse liability; Benzodiazepine; Human volunteer; Subjective effect; Zolpidem

Indexed keywords

PLACEBO; ZOLPIDEM; ZOLPIDEM TARTRATE;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG EFFECT; DRUG MISUSE; FEMALE; HEART RATE; HUMAN; NAUSEA; NORMAL HUMAN; PILOT STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; SINGLE DRUG DOSE; VITAL SIGN;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD PRESSURE; CHLORPROMAZINE; FEMALE; HEART RATE; HUMANS; HYPNOTICS AND SEDATIVES; PENTOBARBITAL; PILOT PROJECTS; PYRIDINES; SKIN TEMPERATURE; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 54049156007     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.09.011     Document Type: Article

References (35)

1. Boulanger-Rostowsky L., Fayet H., Benmoussa N., and Ferrandi J. Dependence on zolpidem: a report of two cases. Encephale 30 (2004) 153-155
2. Cubała W.J., Landowski J., and Wichowicz H.M. Zolpidem abuse, dependence and withdrawal syndrome: sex as susceptibility factor for adverse effects. Br. J. Clin. Pharmacol. 65 (2008) 444-445
3. de las Cuevas C., Sanz E., de la Fuente J.A., Cabrera C., and Mateos A. Prescribed daily doses and 'risk factors' associated with the use of benzodiazepines in primary care. Pharmacoepidemiol. Drug Saf. 8 (1999) 207-216
4. de Wit H., Johanson C.E., and Uhlenhuth E.H. Reinforcing properties of lorazepam in normal volunteer subjects. Drug Alcohol Depend. 13 (1984) 31-41
5. de Wit H., Uhlenhuth E.H., and Johanson C.E. Lack of preference for flurazepam in normal volunteers. Pharmacol. Biochem. Behav. 21 (1984) 865-869
6. de Wit H., Uhlenhuth E.H., and Johanson C.E. Drug preference in normal volunteers: effects of age and time of day. Psychopharmacology 87 (1985) 186-193
7. de Wit H., Pierri J., and Johanson C.E. Assessing pentobarbital preference in normal volunteers using a cumulative dosing procedure. Psychopharmacology 99 (1989) 416-421
8. Evans S.M., Funderburk F.R., and Griffiths R.R. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J. Pharmacol. Exp. Ther. 255 (1990) 1246-1255
9. Evans S.M., Foltin R.W., Levin F.R., and Fischman M.W. Behavioral and subjective effects of DN-2327 (pazinaclone) and alprazolam in normal volunteers. Behav. Pharmacol. 6 (1995) 176-186
10. Greenblatt D.J., Harmatz J.S., von Moltke L.L., Ehrenberg B.L., Harrel L., Corbett K., Counihan M., Graf J.A., Darwish M., Mertzanis P., Martin P.T., Cevallos W.H., and Shader R.I. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin. Pharmacol. Ther. 64 (1998) 553-561
11. Griffiths R.R., and Weerts E.M. Benzodiazepine self-administration in humans and laboratory animals - implications for problems of long-term use and abuse. Psychopharmacology 134 (1997) 1-37
12. Griffiths R.R., Sannerud C.A., Ator N.A., and Brady J.V. Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal. J. Pharmacol. Exp. Ther. 260 (1992) 1199-1208
13. Griffiths R.R., Bigelow G.E., and Ator N.A. Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend. 70 (2003) S41-S54
14. Jaffe J.H., Bloor R., Crome I., Carr M., Alam F., Simmons A., and Meyer R.E. A postmarketing study of relative abuse liability of hypnotic sedative drugs. Addiction 99 (2004) 165-173
15. Jasinski D.R. Assessment of the abuse potential of morphine-like drugs (methods used in man). In: Martin W.R. (Ed). Drug Addiction I Vol. 45/1 (1977), Springer-Verlag, Heidelberg 197-258
16. Krishnan V., and Collop N.A. Gender differences in sleep disorders. Curr. Opin. Pulm. Med. 12 (2006) 383-389
17. Langtry H.D., and Benfield P. Zolpidem: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 40 (1990) 291-313
18. Liappas I.A., Malitas P.N., Dimopoulous N.P., Gitsa O.E., Liappas A.I., Nilolau Ch.K., and Christodoulou G.N. Zolpidem dependence case series: possible neurological mechanisms and clinical management. J. Psychopharmacol. 17 (2003) 131-135
19. Mackowiak P.A., Wasserman S.S., and Levine M.M. A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. JAMA 268 (1992) 1578-1580
20. Morlock R.J., Tan M., and Mitchell D.Y. Patient characteristics and patterns of drug use for sleep complaints in the United States: analysis of National Ambulatory Medical Survey Data, 1997-2002. Clin. Ther. 28 (2006) 1044-1053
21. Olubodun J.O., Ochs H.R., von Moltke L.L., Roubenoff R., Hesse L.M., Harmatz J.S., Shader R.I., and Greenblatt D.J. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br. J. Clin. Pharmacol. 56 (2003) 297-304
22. Rowlett J.K., and Lelas S. Comparison of zolpidem and midazolam self-administration under progressive-ratio schedules: consumer demand and labor supply analyses. Exp. Clin. Psychopharmacol. 15 (2007) 328-337
23. Rowlett J.K., Platt D.M., Lelas S., Atack J.R., and Dawson G.R. Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 915-920
24. Rush C.R., and Baker R.W. Zolpidem and triazolam interact differentially with a delay interval on a digit-enter-and-recall task. Hum. Psychopharmacol. 16 (2001) 147-157
25. Rush C.R., and Griffiths R.R. Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers. J. Clin. Psychopharmacol. 16 (1996) 146-157
26. Rush C.R., Madakasira S., Goldman N.H., Woolverton W.L., and Rowlett J.K. Discriminative stimulus effects of zolpidem in pentobarbital-trained subjects: II. Comparison with triazolam and caffeine in humans. J. Pharmacol. Exp. Ther. 280 (1997) 174-188
27. Rush C.R., Armstrong D.L., Ali J.A., and Pazzaglia P.J. Benzodiazepine-receptor ligands in humans: acute performance-impairing, subject-rated and observer-rated effects. J. Clin. Psychopharmacol. 18 (1998) 1540165
28. Rush C.R., Baker R.W., and Wright K. Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans. Psychopharmacology 144 (1999) 220-233
29. Salva P., and Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Clin. Pharmacokinet. 29 (1995) 142-153
30. Sethi P.K., and Khandelwal D.C. Zolpidem at supratherapeutic doses can cause drug abuse, dependence, and withdrawal seizure. J. Assoc. Phys. India 53 (2005) 139-140
31. Soyka M., Bottlender R., and Moller H.J. Epidemiological evidence for a low abuse potential of zolpidem. Pharmacopsychiatry 33 (2000) 138-141
32. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network, 2005: National Estimates of Drug-Related Emergency Department Visits (2007) DAWN Series D-29, DHS Publication No. (SMA) 07-4256, Rockville MD
33. Troy S.M., Lucki I., Unruh M.A., Cevallos W.H., Leister C.A., Martin P.T., Furlan P.M., and Mangano R. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. J. Clin. Psychopharmacol. 20 (2000) 328-337
34. Wilkinson C.J. The abuse potential of zolpidem administered alone and with alcohol. Pharmacol. Biochem. Behav. 60 (1998) 193-202
35. Woods J.H., Katz J.L., and Winger G. Benzodiazepines: use, abuse, and consequences. Pharmacol. Rev. 44 (1992) 151-347